| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Imperial Cancer Research Fund, Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, England
Within human carcinomas, there is often an infiltration of lymphocytes and other cells of the immune system. A variety of cytokines are produced by such cells that could have a paracrine influence on the growth of tumor epithelium. The effect of one of these cytokines, interleukin-4 (IL-4), on human breast and colon cancer cell lines was therefore examined. IL-4 inhibited the growth of human colon (HT 29) and breast [MCF-7 wild type (MCF-7 WT), MCF-7 Adriamycin-resistant (MCF-7r), MDA-MB-231, and MDA-MB-468] carcinoma cells in culture. Competitive binding of 125I-IL-4 demonstrated the presence of 2000 high affinity IL-4-binding sites on HT 29 cells. The K4 for specific binding of 125I-IL-4 to HT 29 cells was 77 pM. Further studies were conducted on the estrogen-dependent MCF-7 WT and estrogen-independent MDA-MB-231 breast carcinoma lines. Concentrations of IL-4 of 10–100 nM were required to significantly inhibit growth of these carcinoma cell lines; e.g., with MCF-7 WT cells, half-maximal inhibition of growth occurred at 20 nM IL-4. Specific binding of 125I-IL-4 was detected to MCF-7 WT and MDA-MB-231 cells, but the low level of binding precluded Scatchard analysis. IL-4 inhibited 90% of the 17ß-estradiol-stimulated growth of MCF-7 WT cells in a dose-dependent manner but without a change in estrogen receptor expression. Inhibition of growth by IL-4 was less in the absence of estrogens. Combined treatment with IL-4 and other known inhibitors of breast carcinoma cell growth [transforming growth factor-ß1 (TGF-ß1) and the antiestrogen tamoxifen] showed additive inhibition. The hormone-independent cell lines MCF-7r and MDA-MB-231 were additively inhibited by IL-4 and TGF-ß1. This was not the case with MDA-MB-468 cells in which inhibition by IL-4 and TGF-ß1 was of similar magnitude but no significantly greater effect was observed on combined treatment. No secretion of IL-4 was detected from these cell lines either basally or on treatment with TGF-ß1 or tamoxifen, and we conclude that IL-4 is a nonautocrine inhibitor of breast carcinoma cell growth.
1 To whom requests for reprints should be addressed.
Received 8/ 6/91. Accepted 10/30/91.
This article has been cited by other articles:
|
|
 |
|
  S. Wilkening, B. Tavelin, F. Canzian, K. Enquist, R. Palmqvist, A. Altieri, G. Hallmans, K. Hemminki, P. Lenner, and A. Forsti Interleukin promoter polymorphisms and prognosis in colorectal cancer Carcinogenesis, June 1, 2008; 29(6): 1202 - 1206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Shimamura, R. E. Royal, M. Kioi, A. Nakajima, S. R. Husain, and R. K. Puri Interleukin-4 Cytotoxin Therapy Synergizes with Gemcitabine in a Mouse Model of Pancreatic Ductal Adenocarcinoma Cancer Res., October 15, 2007; 67(20): 9903 - 9912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kioi, S. Takahashi, M. Kawakami, K. Kawakami, R. J. Kreitman, and R. K. Puri Expression and Targeting of Interleukin-4 Receptor for Primary and Advanced Ovarian Cancer Therapy Cancer Res., September 15, 2005; 65(18): 8388 - 8396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Simard, M.-L. Ricketts, S. Gingras, P. Soucy, F. A. Feltus, and M. H. Melner Molecular Biology of the 3{beta}-Hydroxysteroid Dehydrogenase/{Delta}5-{Delta}4 Isomerase Gene Family Endocr. Rev., June 1, 2005; 26(4): 525 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. O. Rahaman, M. A. Vogelbaum, and S. J. Haque Aberrant Stat3 Signaling by Interleukin-4 in Malignant Glioma Cells: Involvement of IL-13R{alpha}2 Cancer Res., April 1, 2005; 65(7): 2956 - 2963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Beseth, R. B. Cameron, P. Leland, L. You, F. Varricchio, R. J. Kreitman, R. A. Maki, D. M. Jablons, S. R. Husain, and R. K. Puri Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts Ann. Thorac. Surg., August 1, 2004; 78(2): 436 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Vella, R. Mineo, F. Frasca, E. Mazzon, G. Pandini, R. Vigneri, and A. Belfiore Interleukin-4 Stimulates Papillary Thyroid Cancer Cell Survival: Implications in Patients with Thyroid Cancer and Concomitant Graves' Disease J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2880 - 2889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Conticello, F. Pedini, A. Zeuner, M. Patti, M. Zerilli, G. Stassi, A. Messina, C. Peschle, and R. De Maria IL-4 Protects Tumor Cells from Anti-CD95 and Chemotherapeutic Agents via Up-Regulation of Antiapoptotic Proteins J. Immunol., May 1, 2004; 172(9): 5467 - 5477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Sasaki, H. Mita, M. Toyota, S. Ishida, I. Morimoto, T. Yamashita, T. Tanaka, K. Imai, Y. Nakamura, and T. Tokino Identification of the Interleukin 4 Receptor {alpha} Gene as a Direct Target for p73 Cancer Res., December 1, 2003; 63(23): 8145 - 8152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kawakami, M. Kawakami, P. Leland, and R. K. Puri Internalization Property of Interleukin-4 Receptor {alpha} Chain Increases Cytotoxic Effect of Interleukin-4 Receptor-targeted Cytotoxin in Cancer Cells Clin. Cancer Res., January 1, 2002; 8(1): 258 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kawakami, P. Leland, and R. K. Puri Structure, Function, and Targeting of Interleukin 4 Receptors on Human Head and Neck Cancer Cells Cancer Res., June 1, 2000; 60(11): 2981 - 2987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Opal and V. A. DePalo Anti-Inflammatory Cytokines Chest, April 1, 2000; 117(4): 1162 - 1172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. L.-Y. Chang, X. Peng, and X.-Y. Fu Interleukin-4 Mediates Cell Growth Inhibition through Activation of Stat1 J. Biol. Chem., March 31, 2000; 275(14): 10212 - 10217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gingras, S. Côté, and J. Simard Multiple Signaling Pathways Mediate Interleukin-4-Induced 3{beta}-Hydroxysteroid Dehydrogenase/{Delta}5-{Delta}4 Isomerase Type 1 Gene Expression in Human Breast Cancer Cells Mol. Endocrinol., February 1, 2000; 14(2): 229 - 240. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. Essner, Y. Huynh, T. Nguyen, D. L. Morton, and D. S. B. Hoon FUNCTIONAL INTERLEUKIN 4 RECEPTOR AND INTERLEUKIN 2 RECEPTOR COMMON {gamma}-CHAIN ON HUMAN NON-SMALL CELL LUNG CANCERS: NOVEL TARGETS FOR IMMUNE THERAPY J. Thorac. Cardiovasc. Surg., January 1, 2000; 119(1): 10 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gingras and J. Simard Induction of 3{beta}-Hydroxysteroid Dehydrogenase/ Isomerase Type 1 Expression by Interleukin-4 in Human Normal Prostate Epithelial Cells, Immortalized Keratinocytes, Colon, and Cervix Cancer Cell Lines Endocrinology, October 1, 1999; 140(10): 4573 - 4584. [Abstract] [Full Text]
|
|
|
|
|
|
S. Gingras, R. Moriggl, B. Groner, and J. Simard Induction of 3{beta}-Hydroxysteroid Dehydrogenase/{Delta}5-{Delta}4 Isomerase Type 1 Gene Transcription in Human Breast Cancer Cell Lines and in Normal Mammary Epithelial Cells by Interleukin-4 and Interleukin-13 Mol. Endocrinol., January 1, 1999; 13(1): 66 - 81. [Abstract] [Full Text]
|
|
|
|
 |
|
 O. V. Volpert, T. Fong, A. E. Koch, J. D. Peterson, C. Waltenbaugh, R. I. Tepper, and N. P. Bouck Inhibition of Angiogenesis by Interleukin 4 J. Exp. Med., September 21, 1998; 188(6): 1039 - 1046. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Hawker, P. R. A. Johnson, J. M. Hughes, and J. L. Black Interleukin-4 inhibits mitogen-induced proliferation of human airway smooth muscle cells in culture Am J Physiol Lung Cell Mol Physiol, September 1, 1998; 275(3): L469 - L477. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
